Transmedics Group Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect eight directors to serve until the 2027 Annual Meeting.

2. 2

   Advisory Vote on Executive Compensation (“Say-on-Pay”

   ManagementBoard: FOR

   Non-binding advisory approval of named executive officers’ compensation as disclosed in the proxy statement.

   More detail

   The proposal asks shareholders to cast a non-binding advisory vote to approve the company’s executive compensation as disclosed in the proxy. Management seeks this vote to gauge shareholder support for compensation programs and to demonstrate responsiveness to shareholder feedback; the Compensation Committee uses peer benchmarking and an independent consultant, Pearl Meyer, to set pay elements. The compensation program emphasizes performance-based pay (large portion equity and bonuses tied to revenue and strategic goals), includes clawback and stock ownership guidelines, and has limits like maximum bonus caps and no repricing without shareholder approval. The Board recommends a "FOR" vote, arguing that the program aligns management incentives with shareholder value, supported by strong 2025 financial performance (notably revenue growth and positive cash flow) and prior high say-on-pay support.

3. 3

   Amendment to the Amended and Restated 2019 Stock Incentive Plan

   ManagementBoard: FOR

   Increase share reserve by 2,750,000 shares, extend plan term to June 1, 2036, add minimum one-year vesting for awards granted on/after Jan 1, 2027, and provide double-trigger vesting on change in control.

   More detail

   The proposal asks shareholders to approve an amendment to the 2019 Plan to add 2,750,000 shares, extend the plan term to 2036, impose a one-year minimum vesting for awards granted on or after Jan 1, 2027 (with limited exceptions), and adopt double-trigger vesting on change-in-control events. Management seeks approval because the current share reserve would constrain the company’s ability to grant equity to its rapidly expanded workforce (headcount grew from ~92 at IPO to 898 at year-end 2025) and to remain competitive for talent; the board calculated historical burn rates and expects the proposed increase to provide 1–2 years of runway. The Amended Plan also presents governance protections: no evergreen provision, no liberal share recycling, no repricing without shareholder approval, director compensation limits, and restrictions on dividends on unvested awards. The Board recommends a FOR vote, framing the change as essential to compensate and retain employees while maintaining governance safeguards.

4. 4

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for fiscal year ending Dec 31, 2026.

Upcoming shareholder meetings at Transmedics Group Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Transmedics Group Inc 2026 annual meeting?

Transmedics Group Inc (TMDX) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.

What is the record date for the Transmedics Group Inc 2026 meeting?

The record date for the Transmedics Group Inc 2026 meeting is Wednesday, March 25, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Transmedics Group Inc's 2026 meeting?

The board is presenting 8 director nominees at the Transmedics Group Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Transmedics Group Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Transmedics Group Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.